title: The argument for conservative, delayed surgery in the management of prostatic rhabdomyosarcoma.
abstract: Exenteration is no longer required for most patients who have rhabdomyosarcoma (RMS) of the prostate. This site comprised only about 5% of newly diagnosed cases in the IRS-III (1984-1991). The mean age at the time of diagnosis was 5.3 yrs (range, 0 to 19 years). Most tumors were relatively large, had embryonal histology, and were clinically localized but unresectable without major loss of organ function. The 44 patients with group III tumors (gross residual disease) were treated according to the IRS-III protocol. Forty-three of them underwent biopsy only, and one patient had subtotal resection as the initial procedure. The average number of surgical procedures per patient was two (range, one to five). Six of the 44 patients had no additional surgery. The second-look procedures performed in the other 38 patients included exenteration (14), prostatectomy (7), cystoscopic/perineal needle biopsy (8), laparotomy with biopsy (6), and subtotal excision with bladder salvage (3). Additional surgery was required for four patients, for evaluation of a residual mass, postoperative fistula, ureteral stricture, or small bowel obstruction. Six patients with relapse or residual disease underwent additional chemotherapy and late exenteration (3), prostatectomy (1), or biopsy (2). Four of the six have been cured, one is in treatment for a second malignancy, and the other has residual disease after exenteration. Thirty-six of the 44 patients with group III tumors have been cured (minimum follow-up period, 6 years; range, 6 to 11 years), compared with 23 of the 47 in IRS-II (1978-1984) (P = .001). Two of the six deaths in this group were caused by infection. The bladder salvage rate for those cured of their disease also was better (64% v 57% for IRS-II). The two patients with group IIA tumors were cured by gross primary excision, local radiotherapy, and vincristine and actinomycin therapy. By contrast, all patients with metastatic disease (group IV) died of the tumor. Conservative, delayed surgery, performed after intensive chemotherapy with or without radiotherapy, yields a better cure rate while maintaining a high rate of bladder salvage in children with group III prostatic RMS.
authors.affiliation: Intergroup Rhabdomyosarcoma Study (IRS) Group, Omaha, Nebraska, USA.
authors.forename: T E
authors.initials: TE
authors.lastname: Lobe
authors.forename: E
authors.initials: E
authors.lastname: Wiener
authors.forename: R J
authors.initials: RJ
authors.lastname: Andrassy
authors.forename: C E
authors.initials: CE
authors.lastname: Bagwell
authors.forename: D
authors.initials: D
authors.lastname: Hays
authors.forename: W M
authors.initials: WM
authors.lastname: Crist
authors.forename: B
authors.initials: B
authors.lastname: Webber
authors.forename: J C
authors.initials: JC
authors.lastname: Breneman
authors.forename: M M
authors.initials: MM
authors.lastname: Reed
authors.forename: M C
authors.initials: MC
authors.lastname: Tefft
authors.forename: R
authors.initials: R
authors.lastname: Heyn
mesh_terms: D000293:Adolescent; D000328:Adult; D001707:Biopsy, Needle; D002648:Child; D002675:Child, Preschool; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009367:Neoplasm Staging; D010385:Pelvic Exenteration; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery*; D012086:Reoperation; D012208:Rhabdomyosarcoma / Q000473:pathology / Q000601:surgery*; D013997:Time Factors; D016896:Treatment Outcome